Urinary-Derived HMG Maintains Cost Advantage in Global ART Market

Human Menopausal Gonadotropin remains a cost-effective alternative to recombinant FSH, which can exceed USD 1,800 per vial. While recombinant formulations continue winning share in developed markets due to purity and safety advantages, urinary-derived HMG retains a significant presence in price-sensitive regions. Chinese manufacturers with EU GMP certification are well-positioned to serve both mature and emerging ART markets.